Stocks and Investing Stocks and Investing
Tue, September 26, 2017
Mon, September 25, 2017
Fri, September 22, 2017

Do Kim Maintained (ALNY) at Buy with Increased Target to $134 on, Sep 22nd, 2017


Published on 2024-10-25 22:58:31 - WOPRAI, Do Kim
  Print publication without navigation


Do Kim of BMO Capital, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Buy with Increased Target from $99 to $134 on, Sep 22nd, 2017.

Do has made no other calls on ALNY in the last 4 months.



There are 6 other peers that have a rating on ALNY. Out of the 6 peers that are also analyzing ALNY, 2 agree with Do's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Increased Target to $101 on, Thursday, September 21st, 2017
  • Paul Matteis of "Leerink Swann" Maintained at Hold with Increased Target to $112 on, Thursday, September 21st, 2017


These are the ratings of the 4 analyists that currently disagree with Do


  • Alan Carr of "Needham" Maintained at Strong Buy with Increased Target to $125 on, Thursday, September 21st, 2017
  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $123 on, Thursday, September 21st, 2017
  • Geoff Meacham of "Barclays" Maintained at Buy with Increased Target to $127 on, Thursday, September 21st, 2017
  • Christopher Marai of "Nomura" Initiated at Sell and Held Target at $56 on, Friday, September 15th, 2017
Contributing Sources